Rockville, MD, February 19, 2004 – Rexahn, an emerging, privately-held biopharmaceutical company focusing on the development of first-in-class signal inhibitor therapeutics, announced today that it has submitted a provisional patent application for its Quinazoline-based anti-cancer drug candidates.
Rockville, MD, January 9, 2004 – Rexahn Corporation announced today that that it has received the prestigious $100,000 as a Technology Growth Program (TGP) Grant from Department of Economic development of Montgomery County, Maryland. TGP was created in 1999 to stimulate and facilitate growth and
Rockville, MD, August 7, 2003 – Rexahn Corp. announced today that that it has raised a $2,000,000 through the sale in a private placement of 500,000 shares of common stock to KT&G Corporation. Furthermore, through the MOU on June 24, 2003, KT&G will consider supporting the research and development
Rockville, MD, May 6, 2003 – Rexahn Corp. announced today that it has signed a Collaborative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health. The agreement provides for NCI and Rexahn to investigate the effect of a family of
Rockville, MD, March 20, 2003 – Rexahn Corp. announced today that it has entered into a joint research agreement with the Korea Research Institute of Chemical Technology (KRICT), a quasi-government research institute in Korea. The purpose of this collaboration is to accelerate the discovery of
Rockville, MD, March 20, 2003 – Rexahn Corp. announced today that it has submitted a patent application for its recently discovered anti-cancer drug, RX-0047. The new drug candidate inhibits expression of HIF-1, a human protein that leads to rapid cancer growth.
Rockville, MD, March 18, 2003 – Rexahn Corp. announced today that it has signed a Research Collaboration Agreement with Rexgene Biotech Co. Ltd, a Korean biotech company headquartered in Seoul, Korea. The agreement provides for the companies to develop a research and development plan for the